tively. For hypertensive patients treated with statins (8 included trials) the standardized effect size of DSBP and DDBP was 0.07 (95%CI: -0.07-0.21; pϭ0.33) and -0.12 (95%CI: -0.36-0.11; pϭ0.31), respectively. CONCLUSIONS: Despite previous suggestions, statin therapy in normotensive or hypertensive patients does not lead to reductions in systolic and diastolic blood pressure. Despite these results, however, the routine use of statins, especially in patients with hypertension should be always considered due to the essential reduction of cardiovascular events. OBJECTIVES:The first coronary drug-eluting stent gained its market approval in Europe 2002. Many different drug-eluting stents came to the market worldwide since then. In Taiwan, National Health Insurance has partially reimbursed drugeluting stents since 2006. The number of claimed usage increased from 521 (year 2006) up to 14,311 (year 2010), and total claimed reimburse went up from NTD 15 million to 300 million. The impact to the NHI has been increasing. The aim of this study is to summarize the results of Taiwan drug-eluting stents studies for future researches. METHODS: We systematically searched three bibliographic databases: EMBASE, PubMed and Taiwan National Central Library for studies utilizing Taiwan local data. In order to collect as many local studies as we can, no restrictions were applied on publication year, study type, disease, patients, intervention, comparator and outcomes. RESULTS: Among the 73 studies we identified in EMBASE and PubMed, only one randomized control trial was found. The authors tried to evaluate the preventive outcome of phosphorycholine-coated dexamethasone stent by observing restenosis rate. We then expanded our analysis scopes to controlled trials, and additional 26 studies were identified and 3 studies matched our research question. Their topics were about "1 year follow-up after PCI with Titan versus TAXUS stents", "gender differences in patients undergoing coronary stenting" and "the effects of starting statin therapy before PCI with drug-eluting stents". On the other part of our research at Taiwan National Central Library, there was no paper matched our including criteria. Most of the papers included there were coronary stents design related articles. CONCLUSIONS: Based on systematically research results, we only found one randomized control trial fully used Taiwan local data. Lack of comparative effectiveness on local stents usage could pose a problem when considering evidence-based decision making.
after transplant. Clinical variables are not associated with CMV reactivation: age, gender, stem cells, hematological disease, conditioning regimen, serology status and prior autologous transplant. Twenty-four patients (47.1%) had only one episode of CMV reactivation, 12 (23.5%) had two episodes and 15 (29.3%) had more than two episodes after allo-HSCT. Using filters discussing previously, 221 polymorphisms were detected in D and R. Although 209 variants studied had no apparent impact on the features of CMV reactivation, but we found that 12 variants in 7 different genes were associated significantly with the development or protection of CMV reactivation (Table 1). Our data showed that determined polymorphism in TNF-a, IL12A, TGBF2, IL1RN and CD48 play an important role to protection against CMV. On other hand, KIR3DL1 and CXCL12 represent examples of how receptor polymorphism can influence CMV development. Summary/Conclusion: The data presented suggest that screening of patients and donor pre-transplantation could help to predict the individual risk of the development of CMV infection. These results might also enable the identification of patients at high risk of CMV reactivation, enabling pre-emptive therapy or attempts to cure the infection by administrating antiviral therapy or CMV-specific T lymphocytes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.